Phase II trial of AKT inhibitor MK-2206 in patients with advanced breast cancer who have tumors with PIK3CA or AKT mutations, and/or PTEN loss/PTEN mutation

BACKGROUND: The PI3K/AKT pathway is activated through PIK3CA or AKT1 mutations and PTEN loss in breast cancer. We conducted a phase II trial with an allosteric AKT inhibitor MK-2206 in patients with advanced breast cancer who had tumors with PIK3CA/AKT1 mutations and/or PTEN loss/mutation. METHODS:...

Descripción completa

Detalles Bibliográficos
Autores principales: Xing, Yan, Lin, Nancy U., Maurer, Matthew A., Chen, Huiqin, Mahvash, Armeen, Sahin, Aysegul, Akcakanat, Argun, Li, Yisheng, Abramson, Vandana, Litton, Jennifer, Chavez-MacGregor, Mariana, Valero, Vicente, Piha-Paul, Sarina A., Hong, David, Do, Kim-Anh, Tarco, Emily, Riall, Dianna, Eterovic, Agda Karina, Wulf, Gerburg M., Cantley, Lewis C., Mills, Gordon B., Doyle, L. Austin, Winer, Eric, Hortobagyi, Gabriel N., Gonzalez-Angulo, Ana Maria, Meric-Bernstam, Funda
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6612080/
https://www.ncbi.nlm.nih.gov/pubmed/31277699
http://dx.doi.org/10.1186/s13058-019-1154-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6612080/
https://www.ncbi.nlm.nih.gov/pubmed/31277699
http://dx.doi.org/10.1186/s13058-019-1154-8

Ejemplares similares